ArticleThe New England journal of medicine2017
Osimertinib in EGFR T790M-Positive Lung Cancer.
Article in The New England journal of medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04943406 (The Prognostic Performance of Liquid Biopsy in Peritoneal Lavage and Plasma of Patients With Locally Advanced Gastric Cancer), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Prognostic Performance of Liquid Biopsy in Peritoneal Lavage and Plasma of Patients With Locally Advanced Gastric Cancer (LIQUID Study)
Who cites it
20 citing papers in PubMed.
- Trial
- ELMO2 is a therapeutic vulnerability in mesenchymal-like and drug-resistant non-small cell lung cancer.Nature communications · 2026Article
- The STAT3-ZEB1 axis contributes to CCL2-mediated resistance to osimertinib in lung cancer.Frontiers in oncology · 2026Article
- Development of Furanopyrimidine-Based Orally Active Third-Generation EGFR Inhibitors for the Treatment of Non-Small Cell Lung Cancer.Journal of medicinal chemistry · 2023Article
- CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance.Cancer cell · 2023Article
- Radiolabeled EGFR TKI as predictive imaging biomarkers in NSCLC patients - an overview.Frontiers in oncology · 2022Review
- Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling.Frontiers in oncology · 2022Review
- Preclinical Models for the Study of Lung Cancer Pathogenesis and Therapy Development.Cold Spring Harbor perspectives in medicine · 2021Review
- Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC.Biomarker research · 2021Article
- A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components.Science translational medicine · 2020Article
- Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.Clinical lung cancer · 2020Article
- Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients WithFrontiers in oncology · 2020Article
- Advances in clinical trials of targeted therapy and immunotherapy of lung cancer in 2018.Translational lung cancer research · 2019Review
- The Art of War and oncology: applying the principles of strategy and tactics to greater effect in the era of targeted therapy.Annals of translational medicine · 2018Article
- Personalized medicine in immuno-oncology: a novel prognostic index in non-small cell lung cancer.Journal of thoracic disease · 2018Article
- Characteristics of progression to tyrosine kinase inhibitors predict overall survival in patients with advanced non-small cell lung cancer harboring anJournal of thoracic disease · 2018Article
- Novel Indications for Bruton's Tyrosine Kinase Inhibitors, beyond Hematological Malignancies.Journal of clinical medicine · 2018Review
- A Network Meta-analysis Comparing the Efficacy and Safety of Anti-PD-1 with Anti-PD-L1 in Non-small Cell Lung Cancer.Journal of Cancer · 2018Article
- Systemic treatment of advanced non-small cell lung cancer: controversies and perspectives.Memo · 2018Review
- Medical management of brain metastases.Neuro-oncology advancesReview
Corrections and comments
- Comment on
- Comment on
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
28514610What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.